The appeals court for the Federal Circuit upheld a lower court’s ruling, finding that Regeneron has not sufficiently ...

Regeneron (REGN) faces a 3% stock drop after losing an appeals case over its Eylea drug patents against Amgen (AMGN).

Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

EDT Regeneron (REGN) down 3% after appeals court decision in Amgen (AMGN) patent fightLight Up your Portfolio with Spark:Easily identify ...

Regeneron Pharmaceuticals (REGN) appealed a decision of the United States District Court for the Northern District of West Virginia denying ...

On March 14, 2025, the U.S. Court of Appeals for the Federal Circuit affirmed the District Court for the Northern District of West Virginia’s ...

In re: Xencor, Inc., Appeal No. 2024-1870 (Fed. Cir. Mar. 13, 2025) ...

Amgen expects key drugs like Repatha, Evenity, Tezspire and oncology and rare disease drugs, as well as biosimilars to drive ...

Eylea has been a significant revenue driver for Regeneron, and any potential impact on its sales due to competition from biosimilars is closely watched by investors. The court’s ruling thus represents ...

Adults taking the novel once-daily oral pill for plaque psoriasis have significantly higher rates of clear or almost clear ...

Initial results found that among 1060 participants in 30 countries, the pembrolizumab plus CCRT group conferred better PFS at 24 months than the placebo plus CCRT group (68% vs 57%; hazard ratio [HR], ...